Indraprastha Medical Corporation Ltd vs Syngene International Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Indraprastha Medical Corporation Ltd is ₹ 299.95 as of 23 Oct 15:30 . The P/E Ratio of Indraprastha Medical Corporation Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 years The Market Cap of Indraprastha Medical Corporation Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 years The revenue of Indraprastha Medical Corporation Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Syngene International Ltd for the Jun '26 is ₹ 761.3 crore as compare to the Mar '26 revenue of ₹ 1058 crore. This represent the decline of -28.09% The ebitda of Indraprastha Medical Corporation Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Syngene International Ltd for the Jun '26 is ₹ 102.6 crore as compare to the Mar '26 ebitda of ₹ 319.6 crore. This represent the decline of -67.9% The net profit of Indraprastha Medical Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ -9 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Indraprastha Medical Corporation Ltd changed from 39.1 % on March 2022 to 19.97 % on March 2026 . This represents a CAGR of -12.57% over 5 yearsThe Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 years .

About Indraprastha Medical Corporation Ltd

Indraprastha Medical Corporation Limited was incorporated on 16th March, 1988.
The main business of the Company is to enhance the quality of life of patients by providing comprehensive, high-quality hospital services on a cost-effective basis.
The Company was formed as a joint venture between the Government of Delhi and the Apollo Hospitals Group to establish the Indraprastha Apollo Hospitals. The Hospital provides international standard medical care, offering a wide range of multi-specialty services.
Key specialties with strong growth and revenue potential include transplants, cardiology, oncology, neurology, and orthopaedics. The company came out with the public issue of 2,29,18,300 equity shares of Rs 10 each for cash at par aggregating Rs 22,91,83,000.
IMCL is setting up a multi-disciplinary super speciality teritary care referral hospital at New Delhi.

About Syngene International Ltd

Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Headquartered in India, the operations are driven by its highly qualified teams comprising 5,778scientists and its state-of-the-art facilities, spread over 3 million sq. ft.
The Company operate into 4 business divisions comprising of Discovery Services, Translational & Clinical Research, Dedicated Centers, and Contract Development and Manufacturing Services. Syngene International Limited was incorporated at Bangalore in 1993.
The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
The Company's health-related services extend across all major therapeutic areas and modalities.

FAQs for the comparison of Indraprastha Medical Corporation Ltd and Syngene International Ltd

Which company has a larger market capitalization, Indraprastha Medical Corporation Ltd or Syngene International Ltd?

Market cap of Indraprastha Medical Corporation Ltd is 2,749 Cr while Market cap of Syngene International Ltd is 14,810 Cr

What are the key factors driving the stock performance of Indraprastha Medical Corporation Ltd and Syngene International Ltd?

The stock performance of Indraprastha Medical Corporation Ltd and Syngene International Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Indraprastha Medical Corporation Ltd and Syngene International Ltd?

As of October 25, 2026, the Indraprastha Medical Corporation Ltd stock price is INR ₹299.95. On the other hand, Syngene International Ltd stock price is INR ₹366.9.

How do dividend payouts of Indraprastha Medical Corporation Ltd and Syngene International Ltd compare?

To compare the dividend payouts of Indraprastha Medical Corporation Ltd and Syngene International Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.